GW’s extensive research into the pharmacology of cannabinoids continues to yield highly promising data and new intellectual property across a range of therapeutic areas. GW continues to invest in research to accelerate further growth and value creation through the development of medicines that address serious unmet medical needs.
Pharmaceutical Development Pipeline
Products
Pre-Clinical
Phase 1
Phase 2
Phase 3
Submit
FDA Approved
Epidiolex® (cannabidiol)
PRODUCTS
Epidiolex Dravet Syndrome
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
PRODUCTS
Epidiolex Lennox-Gastaut Syndrome
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
PRODUCTS
Epidiolex Tuberous Sclerosis Complex
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
NABIXIMOLS (marketed as Sativex® ex-US)
PRODUCTS
Sativex MS Spasticity
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
PRODUCTS
Sativex Spinal Cord Injury Spasticity
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
PRODUCTS
Sativex PTSD
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
PRODUCTS
Sativex Other neurological conditions
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
CBDV
PRODUCTS
GWP42006 (CBDV) Epilepsy
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
PRODUCTS
GWP42006 (CBDV) Autism Spectrum Disorders
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
Other
PRODUCTS
GWP42003 Schizophrenia
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
PRODUCTS
GWP42003 (IV) Neonatal Hypoxic-Ischemic Encephalopathy
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
Epidiolex® is an investigational product outside of the United States. Sativex® is not approved in the United States for any indication; it is approved for MS Spasticity in certain countries outside of the United States. All other products mentioned are investigational only. See www.gwpharm.com for full details.